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Results. We identified 7 patients who received cyclophosphamide in pulse doses of 1 g associated with methylprednisolone, 1 g every 2 months (500-700 mg/m 2 , according to each patient's body surface area) as a first-line treatment, within a mean of 17 months from the first demyelinating event (optic neuritis, myelitis, or both) (Table) . During cyclophosphamide therapy, 5 patients continued relapsing and/or worsening, 1 patient died owing to a severe NMO relapse, and 1 abandoned follow-up at our center (Table) ; only 1 patient remained clinically stable. The remaining 5 patients on follow-up were switched to azathioprine associated with prednisone after clinical judgment of cyclophosphamide inefficiency. After treatment modification, there was a decrease in annualized relapse rate and/or progression index, with some patients showing improvement in their Expanded Disability Status Scale scores (Table) . Patient 1 further showed an increase in annualized relapse rate and received rescue therapy with intravenous immunoglobulin every 2 months.
Comment. Neuromyelitis optica is an autoimmune demyelinating disease of the central nervous system characterized by severe relapses of optic neuritis and myelitis, which are the main factors associated with neurologic disability. 6 Therefore, preventing relapses should be the main goal of treatments prescribed for patients with NMO.
In this series of Brazilian patients with relapsing NMO followed up at Federal University of São Paulo, treatment with cyclophosphamide was not able to halt relapses or neurologic disability progression, even being an immunosuppressant with similar mechanism of action to azathioprine (both broadly block DNA and RNA synthesis). Although some relapses were also observed in patients after switching to azathioprine, they were less severe, suggesting that less nervous tissue damage might have occurred, thus allowing better neurologic recovery. The association of NMO-IgG positivity and treatment response could not be established for these patients as this biomarker was only made available in Brazil 
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The reason for cyclophosphamide treatment failure could not be identified solely on clinical information, and we speculate that it might have occurred owing to the doses we used or dosing interval-even though 5 patients presented with a lymphocyte count below 1.000/µL (to convert to ϫ10 9 per liter, multiply by 0.001) while taking the therapy-or even be related to a specific drug mechanism of action, which would be better understood in an experimental setting. Nevertheless, considering the known response of azathioprine, 1 mycophenolate, 3 and rituximab, 2 the results presented here should discourage the use of cyclophosphamide in pulse doses for the treatment of NMO. 1 Although I very much support the IDEAL model to prevent uncontrolled dissemination of unproven or even harmful procedures, this does not mean that any sort of research can be done. The authors stated that the demand by patients with multiple sclerosis for research on endovascular interventions in chronic cerebrospinal venous insufficiency (CCSVI) is so great that any call to halt it would serve only to propel the unregulated and unmonitored off-label practice, which is likely to cause more harm than would carefully monitored clinical trials. What this actually means is that you have to tell your patient during informed consent, when you perform research for CCSVI, that you do this to prevent further unregulated off-label use, which is likely to cause harm. In article 9 of the Declaration of Helsinki, it is stated: "Medical research is subject to ethical standards that promote respect for all human subjects and protect their health and rights." Asking patients to participate in a trial just to prevent unregulated and unmonitored off-label practice means that the researcher does not believe the CCSVI hypothesis is true. The overwhelming accumulation of highquality papers all speaking against CCSVI in the last 2 years, some published in this journal, actually make it impossible to believe that the CCSVI hypothesis is or can be true. Medical research should only be conducted to find an answer to a research question, not to satisfy the popular voice. The original IDEAL paper also stated: "Trials are unnecessary when an advance is clear and substantial." 2 I would argue that the opposite is also true: Trials are also unnecessary when the advance is clearly unproven. Research should be conducted to challenge scientific doubt and when there is no scientific doubt, either positive or negative, any trial is unethical and should not be performed.
